Seattle Genetics
1998
FOUNDED
PUBLIC
STATUS
1K-5K
EMPLOYEES
SGEN
STOCK SYMBOL
4
INVESTMENTS
$107.66
SHARE PRICE
(As of Thursday Closing)
Description
Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other oncology programs in pivotal trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 21823 - 30th Drive South East
- Bothell, WA 98021
- United States
+1 (425) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Seattle Genetics’s full profile, request a free trial.
Seattle Genetics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $62.90 - $122.36 | $18.5B | $106.65 | -$1.88 | 1.2M | 171M |
Seattle Genetics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 14,215,653 | 8,610,790 | 7,243,062 | 6,877,938 |
| Revenue | 801,422 | 654,700 | 482,250 | 418,147 |
| EBITDA | (298,164) | (220,314) | (134,618) | (122,077) |
| Net Income | (304,285) | (222,693) | (125,530) | (140,111) |
| Total Assets | 2,097,537 | 1,503,329 | 877,949 | 838,396 |
| Total Debt | 77,973 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Seattle Genetics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Competitors (45)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genmab | Formerly VC-backed | Copenhagen, Denmark | 000 | 00.000 | 000000000 | 00.000 |
| 00000000 | Formerly VC-backed | Alameda, CA | 000 | 00000 | 0&0 | |
| 000000 | Formerly VC-backed | Monrovia, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000 | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
Seattle Genetics Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 00000000 | 09-Mar-2018 | 000000000000000000 | 00000 | Biotechnology | 0000 0000000 00.0 |
| 0000000-00000 0000 | 01-Oct-2017 | 000000000 00000 00 | 000.00 | Buildings and Property | 0000 0000000 00.0 |
| 00000 00000 000000 | 01-Aug-2017 | 000000000000000000 | 000.00 | Laboratory Services (Healthcare) | 000000 00000 00.0 |
| UNUM Therapeutics | 11-Jun-2015 | Early Stage VC | 0000 | Biotechnology | 0000 0000000 00.0 |
Seattle Genetics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 000000000000 | 11-Jun-2015 | 00000 00000 00 | 0000 | Completed |
|
Seattle Genetics Executive Team (12)
4 Former Executives
You’re viewing 5 of 12 executives. Get the full list »Seattle Genetics Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Clay Siegall Ph.D | Seattle Genetics | Chief Executive Officer & Chairman | 000 0000 | |
| Daniel Welch | Self | Board Member | 000 0000 | |
| David Gryska | Self | Board Member | 000 0000 | |
| Felix Baker Ph.D | Baker Bros. Advisors | Board Member | 000 0000 | |
| John Orwin | Self | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »